The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCizzle Biotech Regulatory News (CIZ)

Share Price Information for Cizzle Biotech (CIZ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.65
Bid: 1.60
Ask: 1.70
Change: 0.00 (0.00%)
Spread: 0.10 (6.25%)
Open: 1.65
High: 1.65
Low: 1.65
Prev. Close: 1.65
CIZ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

18 Feb 2022 15:56

RNS Number : 1832C
Cizzle Biotechnology Holdings PLC
18 February 2022
 

 

 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

 

Cizzle Biotechnology Holdings Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify) iii:

 

3. Details of person subject to the notification obligation iv

Name

Conduit Pharmaceuticals Limited

City and country of registered office (if applicable)

 

4. Full name of shareholder(s) (if different from 3.) v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached vi:

16/02/2022

6. Date on which issuer notified (DD/MM/YYYY):

18/02/2022

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights held

in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

 

8.98%

 

0.00%

 

8.98%

 

25,000,000

Position of previous notification (if applicable)

 

0.00%

 

0.00%

 

0.00%

 

       

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Ordinary Shares

 

GB00BNG2VN02

 

25,000,000

 

0

 

8.98%

 

0.00%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

25,000,000

8.98%

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

 

Type of financial instrument

 

Expiration date x

 

Exercise/ Conversion Period xi

Number of voting rights that may be acquired if

the instrument is exercised/converted.

 

% of voting rights

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expiration date x

Exercise/ Conversion Period xi

Physical or cash Settlement xii

Number of voting rights

 

% of voting rights

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

          

  

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

 

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

 

 

 

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional information xvi

 

     

 

Place of completion

Cayman Islands

Date of completion

17/02/2022

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUWVVRUUUUAAR
Date   Source Headline
30th Apr 20249:12 amRNSFinal results for the year ended 31 December 2023
23rd Apr 202411:20 amRNSHolding(s) in Company
2nd Apr 20247:00 amRNSLicensing and Partnership MoU for North America
26th Mar 20247:00 amRNSPlacing to raise £0.62 million
28th Sep 20237:00 amRNSInterim Results
21st Sep 20237:00 amRNSUpdate on Put Option with Conduit
19th Sep 20237:00 amRNSCompletion of Evaluation Programme with Bio-Techne
8th Sep 20237:03 amRNSExtension of and update on Put Option with Conduit
15th Aug 20237:00 amRNSUpdate on Put Option with Conduit
10th Aug 20237:00 amRNSExpansion of Research Agreement and CIZ1B Update
30th Jun 20235:00 pmRNSTotal Voting Rights
28th Jun 202312:01 pmRNSResult of AGM
12th Jun 20232:15 pmRNSTotal Voting Rights
12th Jun 20237:00 amRNSSubscription to raise £350,000
5th Jun 202312:35 pmRNSPosting of Annual Report and Notice of AGM
15th May 20231:42 pmRNSUpdate on Royalty Sharing Agreement in AZD1656
27th Apr 20237:00 amRNSResults for the year ended 31 December 2022
24th Apr 20237:00 amRNSNew Research Agreement with the University of York
30th Mar 202311:05 amRNSSecond Price Monitoring Extn
30th Mar 202311:00 amRNSPrice Monitoring Extension
17th Mar 20234:35 pmRNSPrice Monitoring Extension
13th Mar 20239:00 amRNSPrice Monitoring Extension
7th Mar 20237:00 amRNSIssue of Options in lieu of salary increases
22nd Feb 20237:52 amRNSHolding(s) in Company
6th Feb 20237:02 amRNSHolding(s) in Company
31st Jan 20235:00 pmRNSTotal Voting Rights
24th Jan 202312:48 pmRNSHolding(s) in Company
20th Dec 20223:17 pmRNSUpdate re. timing of Admission
19th Dec 20227:00 amRNSPut Option re AZD1656 & £115,586 Subscription
23rd Nov 20228:04 amRNSClinical Study for Lung Cancer Detection in China
9th Nov 20227:00 amRNSConduit Pharmaceuticals Proposed Listing
31st Oct 20225:00 pmRNSTotal Voting Rights
4th Oct 20228:00 amRNSAdmission and Total Voting Rights
30th Sep 20225:00 pmRNSTotal Voting Rights
29th Sep 20223:49 pmRNSIssue of Consideration Shares & Option Exercise
28th Sep 20223:05 pmRNSHolding(s) in Company
28th Sep 20227:00 amRNSInterim results
26th Sep 20228:00 amRNSAdmission and Total Voting Rights
21st Sep 202211:23 amRNSSubscription, Facility & Publication of Prospectus
18th Aug 20229:21 amRNSArcadia Clinical Trial Results Published
10th Aug 20224:41 pmRNSSecond Price Monitoring Extn
10th Aug 20224:36 pmRNSPrice Monitoring Extension
11th Jul 20227:15 amEQSHardman & Co Research: Cizzle Biotechnology (CIZ): Considerable progress in first year since listing
5th Jul 20227:00 amRNSUpdate on Development of Proprietary Antibodies
27th Jun 202211:52 amRNSResult of AGM
16th Jun 20227:00 amRNSMarketing Agreement to Enhance Expansion in the US
1st Jun 20227:00 amRNSPosting of Annual Report and Notice of AGM
30th May 20227:00 amRNSResults for the year ended 31 December 2021
6th May 20229:05 amRNSSecond Price Monitoring Extn
6th May 20229:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.